A Phase 2 interventional study of Vadadustat and Epoetin Alfa in Anemia and Dialysis-dependent Chronic Kidney Disease, sponsored by Akebia Therapeutics. Completed at 41 sites in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2022-09-29.
Sponsored by Akebia Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.
Among the 27 studies testing vadadustat in Anemia, this one is the 11th largest by enrollment, is one of 2 that started in 2019, is one of 8 in phase 2, and was the 20th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:
Mackay Memorial Hospital
Ages 18+
vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2019.
This study's enrollment of 175 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 60 across the 27 interventional studies. Of the 23 that completed or were terminated, 18 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 27 have an industry lead sponsor. The 4 most frequent:
Akebia Therapeutics is the lead sponsor of 37 studies on the registry; 3 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 12 (55%) have results posted.
23 studies in Anemia by Akebia Therapeutics: none open now, none under way, none of them phase 3. Of 20 finished, 16 (80%) have results posted.
Among the 23 studies in Anemia by Akebia Therapeutics, this one is the 9th largest by enrollment, is one of 2 that started in 2019, is one of 9 in phase 2, and was the 18th registered.
Akebia Therapeutics’s Anemia studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 27 studies testing vadadustat in Anemia, from their registry updates:
Among Akebia Therapeutics’s 23 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2 open-label efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) study to evaluate oral Vadadustat for the treatment of anemia in hemodialysis participants converting from Epoetin Alfa therapy.
This is a Phase 2, randomized, open-label study to evaluate efficacy and safety of oral Vadadustat for the treatment of anemia in hemodialysis participants converting from Epoetin Alfa therapy. The study will be conducted in two parts running in parallel: Part 1, Main Study in a hemodialysis population on maintenance treatment with Epoetin Alfa; Part 2 is in a hemodialysis population that are erythropoiesis-stimulating agent (ESA) hyporesponders on maintenance treatment with Epoetin Alfa. For all participants (Main and ESA hyporesponder parallel study), the study will include a Screening Period, a Treatment Period, and a Safety Follow-Up Period. PK and PD sampling will be done throughout the study. The aim is to achieve and maintain hemoglobin (Hb) levels within the target range of 10.0 to 11.0 grams per deciliter (g/dL), inclusive, while targeting the middle of the range and minimizing excursions outside the target range.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Eligibility in the Main study and erythropoiesis-stimulating agent (ESA) hyporesponder parallel study is based on the following mean weekly Epoetin Alfa doses:
Two values measured by the central laboratory at least 4 days apart between Screening Visit 1 (SV1) and SV2 as indicated:.
Exclusion Criteria:
For female participants of non-:
For female participants of childbearing potential:
Any other reason, which in the opinion of the Investigator, would make the participant not suitable for participation in the study
Acceptable forms of contraception include:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The initial dose of Vadadustat (300, 450, or 600 milligrams \[mg\]) will be based upon the dose of Epoetin Alfa dose participants had received prior to Vadadustat treatment
Drug: Vadadustat
Participants randomized to Vadadustat (Main and erythropoiesis-stimulating agent \[ESA\] hyporesponder parallel studies) who complete a once-daily dosing regimen treatment period and meet eligibility criteria for transition to three times weekly (TIW) dosing will switch to TIW dosing
Drug: Vadadustat TIW
Epoetin Alfa
Drug: Epoetin Alfa
Vadadustat Tablets 150 mg
Also known as: AKB-6548
Epoetin Alfa
Also known as: Procrit, Epogen
Oral Vadadustat
Mean Change in Hemoglobin (Hb) Between Baseline and the Primary Evaluation Period (PEP)
Change from Baseline in Hb value was calculated as the PEP Hb value minus the Baseline Hb value. The PEP value was the average Hb value from Week 10 to Week 12. The Baseline Hb value was defined as the average of the final two Hb values prior to start of dosing on Day 1.
Time frame: Baseline; Week 10 to Week 12
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence (including a clinically significant abnormal laboratory finding) that occurred in the protocol-specified AE reporting period. An AE included medical conditions, signs, and symptoms not previously observed in the participant that emerged during the protocol-specified AE reporting period, including signs or symptoms associated with pre-existing underlying conditions that were not present prior to the AE reporting period. TEAEs, defined as AEs that began (or pre-existing AEs that worsened) on or after the first dose through each participant's last participation date, are reported.
Time frame: Up to Week 24
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values
Parameters assessed for laboratory values included hematology (excluding the primary and secondary efficacy endpoint results related to Hb), clinical chemistry, lipid profiles, and glucose. The investigator was responsible for reviewing laboratory results for clinically significant changes.
Time frame: Up to Week 24
Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Values
Parameters assessed for vital signs included sitting (at rest for a minimum of 5 minutes) heart rate, respiratory rate, body temperature, and blood pressure. The investigator was responsible for reviewing vital sign values for clinically significant changes.
Time frame: Up to Week 24
Number of Participants Classified as Hb Outliers
The target range for Hb was from 10.0 to 11.0 grams per deciliter (g/dL). Hb outliers included participants with a Hb increase of more than 12.0 g/dL or \<8.0 g/dL and decline in Hb ≥0.5 g/dL from Baseline, and a Hb increase to more than 1.0 g/dL within any 2-week interval during the Study Period.
Time frame: Weeks 13 - 20
Number of Participants With Hb Values Within the Target Range at the PEP
The target range for Hb was from 10.0 to 11.0 g/dL, inclusive. The PEP was comprised of Week 10 to Week 12.
Time frame: Week 10 to Week 12
Mean Change in Hb From the PEP to the Secondary Evaluation Period (SEP) in Participants Who Transitioned to Three Times Per Week (TIW) Vadadustat Dosing After Week 12
Change from PEP was calculated as the SEP value minus the PEP value. The PEP value was the average Hb value from Week 10 to Week 12. The SEP value was the average Hb value from Week 18 to Week 20. For the Main Study, analysis is presented per dose level according to the starting dose in TIW regimen, as well as being presented as a combined arm for "Vadadustat Total (TIW dosing regimen)". For the ESA Hyporesponder Parallel Study, a starting dose classification for TIW dosing regimen was not applicable due to no participants switching from Vadadustat QD to TIW dosing.
Time frame: Week 10 to Week 12; Week 18 to Week 20
Mean Change in Hb Between Baseline and the SEP
Change from Baseline was calculated as the SEP value minus the Baseline value. The Baseline Hb value was defined as the average of the final two Hb values prior to start of dosing on Day 1. The SEP value was the average Hb value from Week 18 to Week 20.
Time frame: Baseline; Week 18 to Week 20
Number of Participants With Hb Values Within the Target Range at the SEP
The target range for Hb was from 10.0 to 11.0 g/dL. The SEP was comprised of Week 18 to Week 20.
Time frame: Week 18 to Week 20
Number of Participants With Hb Values Within the Target Range at the SEP in Participants Who Transitioned to TIW Vadadustat Dosing
The target range for Hb was from 10.0 to 11.0 g/dL. The SEP was comprised of Week 18 to Week 20. For the Main Study, analysis is presented per dose level according to the starting dose in TIW regimen, as well as being presented as a combined arm for "Vadadustat Total (TIW dosing regimen)". For the ESA Hyporesponder Parallel Study, a starting dose classification for TIW dosing regimen was not applicable due to no participants switching from Vadadustat QD to TIW dosing.
Time frame: Week 18 to Week 20
Number of Participants With a Mean Increase in Hb From Baseline to the PEP ≥0.5 g/dL or With Hb Values Within the Target Range at the PEP
The target range for Hb was from 10.0 to 11.0 g/dL. The PEP was comprised of Week 10 to Week 12.
Time frame: Week 10 to Week 12
Number of Participants With a Mean Increase in Hb From Baseline to the SEP ≥0.5 g/dL or With Hb Values Within the Target Range at the SEP
The target range for Hb was from 10.0 to 11.0 grams per g/dL. The SEP was comprised of Week 18 to Week 20.
Time frame: Week 18 to Week 20
Number of Participants Requiring at Least One Intravenous (IV) Elemental Iron Supplementation
Iron supplementation was performed to maintain ferritin ≥200 nanograms/milliliters (ng/mL) and transferrin saturation (TSAT) ≥20%.
Time frame: Up to Week 20
Number of Participants Requiring Erythropoiesis-stimulating Agent (ESA) Rescue
ESA rescue therapy was administered in participants with Hb ≥8.5 g/dL, and was stopped when Hb reached ≥9.0 g/dL.
Time frame: Up to Week 20
Number of Participants Requiring Red Blood Cell (RBC) Transfusion
RBC transfusion was administered as rescue therapy in the event of an acute or severe loss of blood.
Time frame: Up to Week 20
Mean Serum Concentration of Erythropoietin (EPO) for Vadadustat Treatment Groups by Strata of Epoetin Alfa Dose Group
Blood samples were collected from participants at defined time points for the assessment of EPO concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Week 1 (pre-dose), Week 1 +1 (Day 8; pre-dose), Week 11 (pre-dose), and Week 13 (pre-dose)
Mean Change From Baseline in Reticulocyte Count
Blood samples were collected from participants at defined time points for the assessment of reticulocyte count. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Week 1, Week 4, Week 8, Week 11, Week 12, Week 13, Week 16, and Week 20
Mean Change From Baseline in Iron Concentration
Blood samples were collected from participants at defined time points for the assessment of iron indices, including iron concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Week 4, Week 8, Week 12, Week 16, and Week 20
Mean Change From Baseline in Ferritin Concentration
Blood samples were collected from participants at defined time points for the assessment of iron indices, including ferritin concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Week 4, Week 8, Week 12, Week 16, and Week 20
Mean Change From Baseline in Total Iron Binding Capacity
Blood samples were collected from participants at defined time points for the assessment of iron indices, including Total Iron Binding Capacity. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Week 4, Week 8, Week 12, Week 16, and Week 20
Mean Change From Baseline in Hepcidin Concentration
Blood samples were collected from participants at defined time points for the assessment of hepcidin concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
Time frame: Baseline; Week 12 and Week 20
Geometric Mean Maximum Observed Plasma Concentration (Cmax) of Vadadustat Following a Single Dose
Blood samples were collected from participants at defined time points for the assessment of Cmax of Vadadustat following a single dose.
Time frame: Day 1; Week 1, Week 1 +1 (Day 8), Week 11, Week 13: pre-dose, 2 hours (h), 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
Geometric Mean Area Under the Concentration-time Curve (AUC) From Time 0 to 24 Hours (AUC0-24) of Vadadustat Following a Single Dose
Blood samples were collected from participants at defined time points for the assessment of AUC and AUC0-24 of Vadadustat following a single dose.
Time frame: Day 1; Week 1, Week 1 +1 (Day 8), Week 11: pre-dose, 2h, 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
Median Terminal Half-life (t1/2) of Vadadustat Following a Single Dose
Blood samples were collected from participants at defined time points for the assessment of t1/2 of Vadadustat following a single dose.
Time frame: Day 1; Week 1, Week 1 +1 (Day 8), Week 11, Week 13: pre-dose, 2 hours (h), 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
Median Time to Reach Cmax (Tmax) of Vadadustat Following a Single Dose
Blood samples were collected from participants at defined time points for the assessment of Tmax of Vadadustat following a single dose.
Time frame: Day 1; Week 1, Week 1 +1 (Day 8), Week 11, Week 13: pre-dose, 2 hours (h), 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
Geometric Mean Elimination Rate Constant (λz) of Vadadustat Following a Single Dose
Blood samples were collected from participants at defined time points for the assessment of λz of Vadadustat following a single dose.
Time frame: Day 1; Week 1, Week 1 +1 (Day 8), Week 11, Week 13: pre-dose, 2 hours (h), 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
Geometric Mean Apparent Total Body Clearance (CLss/F) of Vadadustat Following a Single Dose
Blood samples were collected from participants at defined time points for the assessment of CLss/F of Vadadustat following a single dose.
Time frame: Day 1; Week 1, Week 1 +1 (Day 8), Week 11: pre-dose, 2h, 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
Geometric Mean Apparent Volume of Distribution (Vz/F) of Vadadustat Following a Single Dose
Blood samples were collected from participants at defined time points for the assessment of Vz/F of Vadadustat following a single dose.
Time frame: Day 1; Week 1, Week 1 +1 (Day 8), Week 11: pre-dose, 2h, 3.5h, and 5h post-dose, and additionally at 7h and 10.5h post-dose
| Milestone | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Started | 35 | 34 | 23 | 18 | 21 | 21 | 13 | 5 | 5 |
| Completed | 27 | 23 | 22 | 8 | 12 | 8 | 10 | 3 | 2 |
| Not completed | 8 | 11 | 1 | 10 | 9 | 13 | 3 | 2 | 3 |
| Withdrew: Adverse event | 1 | 2 | 0 | 0 | 2 | 5 | 0 | 2 | 0 |
| Withdrew: Physician decision | 2 | 2 | 0 | 0 | 2 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 2 | 0 | 3 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Study drug put on hold | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Due to urgent safety measures letter | 1 | 2 | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Kidney transplantation | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Participant was on rescue epogen | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Placed on dose hold until end of treatment | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Met exclusion criteria | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Investigational product noncompliance | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Participant relocation | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Eurofin issue | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Noncompliance with site instructions | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Participant's last dose prior to end of treatment | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Changes in hemoglobin values | 1 | 2 | 1 | 0 | 0 | 2 | 1 | 0 | 1 |
Change from Baseline in Hb value was calculated as the PEP Hb value minus the Baseline Hb value. The PEP value was the average Hb value from Week 10 to Week 12. The Baseline Hb value was defined as the average of the final two Hb values prior to start of dosing on Day 1.
| grams per deciliter (g/dL) | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 10.223 ± 0.5805 | 10.059 ± 0.6769 | 10.165 ± 0.6806 | 9.778 ± 0.6832 | 10.288 ± 0.5445 | 10.095 ± 0.7150 | 9.950 ± 0.7950 | 9.530 ± 0.2864 | 9.620 ± 0.6925 |
| Change from Baseline at PEP | -0.371 ± 0.8920 | 0.072 ± 1.1353 | 0.160 ± 0.7519 | -0.911 ± 1.3515 | -0.284 ± 1.0383 | -0.418 ± 1.2752 | 0.268 ± 1.0087 | -0.671 ± 0.7643 | -0.290 ± 1.7730 |
An adverse event (AE) was defined as any untoward medical occurrence (including a clinically significant abnormal laboratory finding) that occurred in the protocol-specified AE reporting period. An AE included medical conditions, signs, and symptoms not previously observed in the participant that emerged during the protocol-specified AE reporting period, including signs or symptoms associated with pre-existing underlying conditions that were not present prior to the AE reporting period. TEAEs, defined as AEs that began (or pre-existing AEs that worsened) on or after the first dose through each participant's last participation date, are reported.
| Participants | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 18 | 27 | 13 | 12 | 14 | 13 | 9 | 5 | 3 |
Parameters assessed for laboratory values included hematology (excluding the primary and secondary efficacy endpoint results related to Hb), clinical chemistry, lipid profiles, and glucose. The investigator was responsible for reviewing laboratory results for clinically significant changes.
| Participants | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Parameters assessed for vital signs included sitting (at rest for a minimum of 5 minutes) heart rate, respiratory rate, body temperature, and blood pressure. The investigator was responsible for reviewing vital sign values for clinically significant changes.
| Participants | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes From Baseline in Vital Sign Values | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The target range for Hb was from 10.0 to 11.0 grams per deciliter (g/dL). Hb outliers included participants with a Hb increase of more than 12.0 g/dL or \<8.0 g/dL and decline in Hb ≥0.5 g/dL from Baseline, and a Hb increase to more than 1.0 g/dL within any 2-week interval during the Study Period.
| Participants | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Hb >12.0 g/dL | 2 | 2 | 3 | 0 | 1 | 0 | 1 | 0 | 0 |
| Hb >13.0 g/dL | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hb >14.0 g/dL | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hb <8.0 g/dL and decline in Hb ≥0.5 g/dL from Baseline | 2 | 2 | 0 | 1 | 1 | 3 | 1 | 1 | 1 |
| Hb increase >1.0 g/dL within any 2-week interval | 4 | 8 | 4 | 4 | 2 | 3 | 6 | 0 | 2 |
The target range for Hb was from 10.0 to 11.0 g/dL, inclusive. The PEP was comprised of Week 10 to Week 12.
| Participants | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Hb Values Within the Target Range at the PEP | 12 | 13 | 15 | 1 | 4 | 4 | 6 | 0 | 0 |
Change from PEP was calculated as the SEP value minus the PEP value. The PEP value was the average Hb value from Week 10 to Week 12. The SEP value was the average Hb value from Week 18 to Week 20. For the Main Study, analysis is presented per dose level according to the starting dose in TIW regimen, as well as being presented as a combined arm for "Vadadustat Total (TIW dosing regimen)". For the ESA Hyporesponder Parallel Study, a starting dose classification for TIW dosing regimen was not applicable due to no participants switching from Vadadustat QD to TIW dosing.
| g/dL | Vadadustat 300 mg (Starting Dose in TIW Dosing Regimen) | Vadadustat 450 mg (Starting Dose in TIW Dosing Regimen) | Vadadustat 600 mg (Starting Dose in TIW Dosing Regimen) | Vadadustat 750 mg (Starting Dose in TIW Dosing Regimen) | Vadadustat Total (TIW Dosing Regimen) | ESA Hyporesponder Parallel Study: Vadadustat ≤ 750 mg (TIW Dosing Regimen) |
|---|---|---|---|---|---|---|
| Mean Change in Hb From the PEP to the Secondary Evaluation Period (SEP) in Participants Who Transitioned to Three Times Per Week (TIW) Vadadustat Dosing After Week 12 | -0.050 ± NA | -1.021 ± 1.0961 | -0.360 ± 0.4894 | -0.103 ± 1.9225 | -0.422 ± 1.1708 | — |
Change from Baseline was calculated as the SEP value minus the Baseline value. The Baseline Hb value was defined as the average of the final two Hb values prior to start of dosing on Day 1. The SEP value was the average Hb value from Week 18 to Week 20.
| g/dL | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Mean Change in Hb Between Baseline and the SEP | -0.197 ± 1.1597 | -0.186 ± 0.8703 | 0.070 ± 0.9545 | 0.114 ± 1.0242 | -0.421 ± 0.8370 | -0.545 ± 0.9771 | 0.343 ± 0.8897 | -0.283 ± 0.7371 | -0.400 ± 1.0157 |
The target range for Hb was from 10.0 to 11.0 g/dL. The SEP was comprised of Week 18 to Week 20.
| Participants | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Hb Values Within the Target Range at the SEP | 6 | 7 | 9 | 2 | 3 | 2 | 6 | 1 | 1 |
The target range for Hb was from 10.0 to 11.0 g/dL. The SEP was comprised of Week 18 to Week 20. For the Main Study, analysis is presented per dose level according to the starting dose in TIW regimen, as well as being presented as a combined arm for "Vadadustat Total (TIW dosing regimen)". For the ESA Hyporesponder Parallel Study, a starting dose classification for TIW dosing regimen was not applicable due to no participants switching from Vadadustat QD to TIW dosing.
| Participants | Vadadustat 300 mg (Starting Dose in TIW Dosing Regimen) | Vadadustat 450 mg (Starting Dose in TIW Dosing Regimen) | Vadadustat 600 mg (Starting Dose in TIW Dosing Regimen) | Vadadustat 750 mg (Starting Dose in TIW Dosing Regimen) | Vadadustat Total (TIW Dosing Regimen) | ESA Hyporesponder Parallel Study: Vadadustat ≤ 750 mg (TIW Dosing Regimen) |
|---|---|---|---|---|---|---|
| Number of Participants With Hb Values Within the Target Range at the SEP in Participants Who Transitioned to TIW Vadadustat Dosing | 0 | 2 | 2 | 3 | 7 | — |
The target range for Hb was from 10.0 to 11.0 g/dL. The PEP was comprised of Week 10 to Week 12.
| Participants | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With a Mean Increase in Hb From Baseline to the PEP ≥0.5 g/dL or With Hb Values Within the Target Range at the PEP | 14 | 19 | 18 | 1 | 6 | 6 | 8 | 0 | 1 |
The target range for Hb was from 10.0 to 11.0 grams per g/dL. The SEP was comprised of Week 18 to Week 20.
| Participants | Stratum 1 (Epoetin Alfa ≤90 U/kg/Week): Vadadustat 300 mg | Stratum 1 (Epoetin Alfa ≤90 U/kg/Week): Vadadustat 450 mg | Stratum 1 (Epoetin Alfa ≤90 U/kg/Week): Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder (Epoetin Alfa ≥300 U/kg/Week): Vadadustat 600 mg | ESA Hyporesponder (Epoetin Alfa ≥300 U/kg/Week): Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With a Mean Increase in Hb From Baseline to the SEP ≥0.5 g/dL or With Hb Values Within the Target Range at the SEP | 10 | 11 | 14 | 3 | 5 | 2 | 8 | 1 | 2 |
Iron supplementation was performed to maintain ferritin ≥200 nanograms/milliliters (ng/mL) and transferrin saturation (TSAT) ≥20%.
| Participants | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Requiring at Least One Intravenous (IV) Elemental Iron Supplementation | 23 | 21 | 16 | 10 | 14 | 18 | 10 | 4 | 5 |
ESA rescue therapy was administered in participants with Hb ≥8.5 g/dL, and was stopped when Hb reached ≥9.0 g/dL.
| Participants | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Requiring Erythropoiesis-stimulating Agent (ESA) Rescue | 2 | 8 | 3 | 5 | 5 | 3 | 1 | 3 | 1 |
RBC transfusion was administered as rescue therapy in the event of an acute or severe loss of blood.
| Participants | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Requiring Red Blood Cell (RBC) Transfusion | 0 | 1 | 0 | 3 | 1 | 2 | 0 | 1 | 1 |
Blood samples were collected from participants at defined time points for the assessment of EPO concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| Milliunits per milliliter | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | ESA Hyporesponder: Vadadustat 600 mg |
|---|---|---|---|---|---|---|
| Baseline | 7.33 ± 57.3 | 9.53 ± 54.0 | 9.93 ± 83.6 | 8.77 ± 48.2 | 6.98 ± 61.6 | 8.03 ± 53.2 |
| Week 1 | 12.1 ± 94.3 | 17.5 ± 97.0 | 15.3 ± 72.6 | 14.1 ± 86.4 | 20.2 ± 90.8 | 12.9 ± 54.2 |
| Week 1 +1 (Day 8) | 15.6 ± 76.3 | 18.9 ± 98.2 | 16.1 ± 76.0 | 18.0 ± 49.8 | 17.4 ± 104.8 | 9.49 ± 37.1 |
| Week 11 | 14.2 ± 55.9 | 14.9 ± 106.2 | 19.4 ± 78.0 | 20.6 ± 169.6 | 17.3 ± 53.4 | — |
| Week 13 | — | 15.7 ± 107.2 | 39.2 ± NA | — | 10.5 ± 47.1 | — |
Blood samples were collected from participants at defined time points for the assessment of reticulocyte count. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| 10^3 cells/microliter (µL) | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 51.9 ± 27.57 | 47.2 ± 17.81 | 48.8 ± 27.27 | 59.3 ± 42.02 | 48.4 ± 33.45 | 51.5 ± 25.14 | 62.6 ± 25.88 | 77.6 ± 51.04 | 83.0 ± 45.34 |
| Week 1 | 3.1 ± 24.09 | 6.9 ± 30.60 | 1.0 ± 22.42 | -18.1 ± 24.81 | -3.9 ± 28.51 | -6.6 ± 33.80 | 20.4 ± 48.64 | -35.8 ± 45.06 | -25.2 ± 29.73 |
| Week 4 | 14.6 ± 32.25 | 14.9 ± 29.45 | 0.8 ± 40.68 | -5.6 ± 37.38 | 2.9 ± 39.68 | 6.1 ± 33.24 | 22.5 ± 50.53 | -26.8 ± 55.44 | 17.5 ± 26.21 |
| Week 8 | 14.0 ± 31.40 | 23.9 ± 39.26 | 23.1 ± 38.98 | 9.1 ± 46.38 | 20.4 ± 49.42 | 23.1 ± 20.33 | 14.0 ± 54.60 | -3.3 ± 67.56 | -21.8 ± 69.36 |
| Week 11 | 11.7 ± 25.06 | 20.2 ± 25.80 | 21.0 ± 35.12 | 26.2 ± 26.2 | 32.5 ± 70.42 | 9.2 ± 41.30 | 3.9 ± 46.15 | -6.7 ± 76.89 | -27.2 ± 71.36 |
| Week 12 | 16.1 ± 32.60 | 16.3 ± 34.27 | 22.2 ± 26.72 | 47.7 ± 66.66 | 20.3 ± 44.30 | 26.9 ± 52.64 | 4.6 ± 39.53 | 3.8 ± 52.72 | -17.3 ± 67.06 |
| Week 13 | 16.7 ± 27.07 | 12.1 ± 43.12 | 16.4 ± 26.53 | 46.3 ± 57.25 | 15.9 ± 43.79 | 10.5 ± 28.80 | 0.1 ± 46.05 | 2.0 ± 83.44 | 16.3 ± 11.93 |
| Week 16 | 13.9 ± 35.40 | 19.6 ± 37.61 | 8.3 ± 34.16 | -2.2 ± 57.32 | 9.7 ± 30.17 | 0.2 ± 22.08 | 26.6 ± 55.82 | -31.5 ± 86.97 | 4.0 ± 16.21 |
| Week 20 | 14.5 ± 25.74 | 13.2 ± 24.50 | 23.8 ± 26.49 | 10.3 ± 41.33 | 16.4 ± 35.54 | 10.9 ± 29.81 | 38.5 ± 44.11 | -3.3 ± 52.58 | 40.0 ± 7.07 |
Blood samples were collected from participants at defined time points for the assessment of iron indices, including iron concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| micrograms per deciliter (µg/dL) | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 87.4 ± 38.46 | 93.9 ± 36.56 | 90.1 ± 35.09 | 57.7 ± 26.71 | 80.9 ± 36.94 | 73.1 ± 22.23 | 65.7 ± 23.93 | 81.6 ± 37.01 | 58.4 ± 18.77 |
| Week 4 | -8.0 ± 34.49 | -11.2 ± 33.59 | -18.3 ± 22.83 | 3.3 ± 35.23 | 9.6 ± 29.67 | 1.7 ± 23.37 | -6.6 ± 32.86 | 8.6 ± 17.36 | 3.8 ± 25.79 |
| Week 8 | -5.5 ± 45.04 | -15.0 ± 40.51 | -8.6 ± 44.30 | 4.5 ± 24.06 | -5.9 ± 36.91 | 11.7 ± 40.33 | -12.6 ± 26.55 | 0.3 ± 11.09 | 2.0 ± 20.33 |
| Week 12 | -2.7 ± 38.24 | -22.2 ± 43.14 | -26.0 ± 33.03 | -2.8 ± 40.49 | -0.4 ± 40.20 | -5.1 ± 27.54 | -16.1 ± 22.88 | -2.5 ± 43.94 | -12.6 ± 28.99 |
| Week 16 | -22.8 ± 39.39 | -18.3 ± 39.85 | -17.9 ± 53.89 | -0.7 ± 10.26 | 5.2 ± 30.27 | -4.6 ± 30.31 | -13.9 ± 44.05 | 19.5 ± 53.03 | -12.0 ± 24.06 |
| Week 20 | -14.2 ± 41.11 | -9.5 ± 27.87 | -16.6 ± 46.49 | 28.7 ± 67.73 | -3.1 ± 32.43 | 13.4 ± 16.03 | -8.4 ± 28.94 | -15.3 ± 43.19 | -10.3 ± 21.57 |
Blood samples were collected from participants at defined time points for the assessment of iron indices, including ferritin concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| micrograms per liter (µg/L) | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 939.3 ± 478.64 | 1043.6 ± 359.10 | 919.3 ± 298.27 | 910.2 ± 408.03 | 745.2 ± 362.98 | 739.5 ± 329.66 | 723.6 ± 484.29 | 1182.2 ± 508.67 | 449.6 ± 423.44 |
| Week 4 | -30.1 ± 185.45 | -101.9 ± 204.51 | -23.7 ± 274.39 | 41.4 ± 335.00 | 152.9 ± 347.97 | 45.5 ± 320.50 | -145.6 ± 211.10 | 34.8 ± 470.43 | -61.5 ± 17.37 |
| Week 8 | -120.8 ± 273.28 | -185.4 ± 298.19 | 24.9 ± 334.28 | 29.4 ± 361.29 | -5.6 ± 255.10 | -87.8 ± 285.30 | -78.3 ± 254.98 | 111.3 ± 609.61 | 397.8 ± 453.76 |
| Week 12 | -118.5 ± 220.40 | -194.8 ± 288.47 | -42.4 ± 356.19 | -68.0 ± 275.11 | -23.8 ± 303.39 | -30.1 ± 386.24 | -195.3 ± 304.63 | -0.5 ± 237.99 | -35.0 ± 157.46 |
| Week 16 | -92.0 ± 309.88 | -70.9 ± 288.34 | 99.5 ± 567.19 | -144.0 ± 358.78 | 27.8 ± 244.67 | -97.2 ± 188.15 | -81.8 ± 447.01 | 80.0 ± 243.24 | 62.3 ± 186.15 |
| Week 20 | -113.6 ± 327.06 | -166.6 ± 298.67 | 26.5 ± 497.52 | -199.4 ± 370.32 | 4.8 ± 331.76 | -51.6 ± 253.07 | -104.8 ± 347.53 | 249.0 ± 636.33 | 607.0 ± 607.0 |
Blood samples were collected from participants at defined time points for the assessment of iron indices, including Total Iron Binding Capacity. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| µg/dL | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 237.8 ± 39.28 | 230.7 ± 39.09 | 234.8 ± 44.76 | 210.1 ± 33.33 | 235.7 ± 38.80 | 223.6 ± 34.31 | 218.2 ± 33.80 | 211.0 ± 42.99 | 225.6 ± 98.15 |
| Week 4 | 35.9 ± 27.11 | 27.7 ± 33.58 | -13.4 ± 26.02 | 27.6 ± 28.49 | 41.0 ± 26.22 | 48.2 ± 37.78 | -0.5 ± 21.44 | 44.2 ± 53.58 | 7.8 ± 14.38 |
| Week 8 | 30.3 ± 28.42 | 37.0 ± 40.99 | -1.1 ± 18.38 | 26.3 ± 23.98 | 49.4 ± 27.34 | 58.8 ± 24.54 | -7.4 ± 19.26 | 56.0 ± 58.15 | -24.8 ± 58.79 |
| Week 12 | 42.4 ± 27.10 | 37.2 ± 43.09 | -9.9 ± 25.85 | 25.1 ± 33.90 | 41.0 ± 39.05 | 54.5 ± 44.05 | -3.8 ± 25.42 | 58.0 ± 14.45 | -0.6 ± 15.32 |
| Week 16 | 35.0 ± 43.00 | 27.8 ± 35.16 | -3.0 ± 25.44 | 55.3 ± 28.63 | 53.1 ± 58.33 | 60.9 ± 70.50 | -13.7 ± 31.46 | 42.5 ± 62.93 | -2.5 ± 18.52 |
| Week 20 | 38.0 ± 28.15 | 44.9 ± 30.71 | -9.5 ± 29.29 | 51.7 ± 37.50 | 68.4 ± 43.40 | 67.9 ± 58.44 | -5.4 ± 29.78 | 66.7 ± 35.22 | -6.0 ± 21.79 |
Blood samples were collected from participants at defined time points for the assessment of hepcidin concentration. Change from Baseline was calculated as the post-Baseline value minus the Baseline value.
| nanograms per milliliter (ng/mL) | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 194.870 ± 113.9348 | 208.816 ± 85.1667 | 259.161 ± 134.9995 | 185.852 ± 105.6611 | 215.608 ± 130.7350 | 160.760 ± 102.6261 | 143.519 ± 124.6749 | 239.958 ± 151.3859 | 74.748 ± 40.2119 |
| Week 12 | -50.565 ± 57.6474 | -53.675 ± 92.1185 | -66.646 ± 152.3178 | -55.283 ± 77.1648 | -34.868 ± 89.7176 | -74.797 ± 126.1667 | -62.787 ± 96.1842 | -128.587 ± 262.6300 | -1.062 ± 30.4842 |
| Week 20 | -86.025 ± 100.4382 | -38.627 ± 75.0555 | -83.685 ± 95.7049 | -93.412 ± 115.2839 | -83.012 ± 98.7521 | -43.701 ± 80.8411 | -80.680 ± 125.2481 | -152.243 ± 218.9284 | -9.023 ± 80.4001 |
Blood samples were collected from participants at defined time points for the assessment of Cmax of Vadadustat following a single dose.
| Micrograms per milliliter (μg/mL) | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | ESA Hyporesponder: Vadadustat 600 mg |
|---|---|---|---|---|---|---|
| Week 1 | 26.0 ± 87.9 | 40.8 ± 54.8 | 26.5 ± 59.3 | 47.0 ± 38.2 | 56.5 ± 39.2 | 44.2 ± 73.1 |
| Week 1 +1 (Day 8) | 20.1 ± 174.4 | 37.6 ± 78.9 | 23.8 ± 69.0 | 44.2 ± 29.6 | 60.1 ± 41.6 | 31.6 ± 151.6 |
| Week 11 | 28.6 ± 49.3 | 24.4 ± 350.6 | 32.4 ± 26.9 | 38.1 ± 99.0 | 41.2 ± 77.7 | — |
| Week 13 | — | 30.6 ± 102.7 | 11.5 ± NA | — | 60.2 ± 9.2 | — |
Blood samples were collected from participants at defined time points for the assessment of AUC and AUC0-24 of Vadadustat following a single dose.
| hours*µg/mL | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | ESA Hyporesponder: Vadadustat 600 mg |
|---|---|---|---|---|---|---|
| Week 1 | 338 ± 63.8 | 518 ± 71.1 | 342 ± 81.7 | 605 ± 54.5 | 786 ± 36.6 | 464 ± 80.9 |
| Week 1 +1 (Day 8) | 289 ± 76.6 | 465 ± 80.8 | 310 ± 94.7 | 566 ± 41.1 | 847 ± 54.8 | 388 ± 112.4 |
| Week 11 | 344 ± 53.5 | 338 ± 282.0 | 402 ± 70.8 | 450 ± 68.2 | 588 ± 52.5 | — |
Blood samples were collected from participants at defined time points for the assessment of t1/2 of Vadadustat following a single dose.
| Hours | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | ESA Hyporesponder: Vadadustat 600 mg |
|---|---|---|---|---|---|---|
| Week 1 | 8.53 (5.36 to 26.6) | 10.5 (3.26 to 21.1) | 12.5 (7.33 to 20.7) | 10.3 (6.33 to 18.3) | 11.0 (6.51 to 18.0) | 9.01 (8.45 to 9.58) |
| Week 1 +1 (Day 8) | 8.82 (5.80 to 22.9) | 8.83 (4.98 to 70.0) | 10.1 (4.79 to 17.9) | 12.4 (5.73 to 47.8) | 14.6 (5.61 to 31.3) | 11.7 (11.3 to 12.0) |
| Week 11 | 6.73 (3.55 to 22.1) | 10.4 (6.46 to 13.8) | 6.49 (3.22 to 9.75) | 3.95 (3.95 to 3.95) | 5.65 (5.26 to 7.12) | — |
| Week 13 | — | 11.0 (11.0 to 11.0) | — | — | 5.01 (5.01 to 5.01) | — |
Blood samples were collected from participants at defined time points for the assessment of Tmax of Vadadustat following a single dose.
| Hours | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | ESA Hyporesponder: Vadadustat 600 mg |
|---|---|---|---|---|---|---|
| Week 1 | 2.08 (0.00 to 11.50) | 2.72 (1.83 to 5.03) | 3.48 (1.92 to 10.50) | 3.50 (1.58 to 9.00) | 2.00 (1.75 to 5.03) | 3.28 (1.83 to 4.50) |
| Week 1 +1 (Day 8) | 3.28 (1.75 to 6.75) | 2.11 (0.00 to 5.23) | 3.33 (1.80 to 5.00) | 3.30 (0.00 to 5.00) | 2.17 (1.75 to 5.05) | 3.42 (1.80 to 4.50) |
| Week 11 | 3.23 (0.00 to 4.50) | 3.50 (1.75 to 10.83) | 3.50 (2.00 to 4.67) | 2.03 (1.75 to 3.63) | 2.11 (1.80 to 5.00) | — |
| Week 13 | — | 1.98 (1.75 to 5.00) | 4.25 (4.25 to 4.25) | — | 2.04 (1.97 to 2.12) | — |
Blood samples were collected from participants at defined time points for the assessment of λz of Vadadustat following a single dose.
| 1/hour | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | ESA Hyporesponder: Vadadustat 600 mg |
|---|---|---|---|---|---|---|
| Week 1 | 0.0797 ± 38.7 | 0.0665 ± 50.5 | 0.0560 ± 41.6 | 0.0681 ± 32.7 | 0.0608 ± 46.9 | 0.0771 ± 8.9 |
| Week 1 +1 (Day 8) | 0.0720 ± 44.2 | 0.0615 ± 70.0 | 0.0714 ± 53.9 | 0.0469 ± 72.2 | 0.0469 ± 74.4 | 0.0594 ± 4.5 |
| Week 11 | 0.0925 ± 65.5 | 0.0687 ± 26.5 | 0.124 ± 92.0 | 0.175 ± NA | 0.116 ± 15.9 | — |
| Week 13 | — | 0.0632 ± NA | — | — | 0.138 ± NA | — |
Blood samples were collected from participants at defined time points for the assessment of CLss/F of Vadadustat following a single dose.
| liters per hour | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | ESA Hyporesponder: Vadadustat 600 mg |
|---|---|---|---|---|---|---|
| Week 1 | 0.888 ± 63.8 | 0.869 ± 71.1 | 0.877 ± 81.7 | 0.744 ± 54.5 | 0.763 ± 36.6 | 1.29 ± 80.9 |
| Week 1 +1 (Day 8) | 1.04 ± 76.6 | 0.967 ± 80.8 | 0.968 ± 94.7 | 0.795 ± 41.1 | 0.708 ± 54.8 | 1.55 ± 112.4 |
| Week 11 | 0.872 ± 53.5 | 1.33 ± 282.0 | 0.747 ± 70.8 | 1.00 ± 68.2 | 1.02 ± 52.5 | — |
Blood samples were collected from participants at defined time points for the assessment of Vz/F of Vadadustat following a single dose.
| Liters | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | ESA Hyporesponder: Vadadustat 600 mg |
|---|---|---|---|---|---|---|
| Week 1 | 10.9 ± 36.2 | 14.3 ± 53.4 | 13.7 ± 69.7 | 12.1 ± 38.6 | 13.8 ± 16.7 | 15.8 ± 56.9 |
| Week 1 +1 (Day 8) | 12.5 ± 36.6 | 13.7 ± 41.0 | 17.4 ± 50.4 | 15.3 ± 67.4 | 15.6 ± 27.2 | 12.4 ± 35.8 |
| Week 11 | 10.2 ± 28.7 | 10.7 ± 37.6 | 10.1 ± 10.3 | 8.24 ± NA | 8.76 ± 18.9 | — |
Collected over Up to Week 24 (from first dose of study drug to last dose + 4 weeks of follow-up). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low Dose of Epoetin Alfa: Vadadustat 300 mg | 0/34 (0%) | 9/34 (26.5%) | 11/34 (32.4%) |
| Low Dose of Epoetin Alfa: Vadadustat 450 mg | 0/35 (0%) | 7/35 (20%) | 20/35 (57.1%) |
| Low Dose of Epoetin Alfa: Epoetin Alfa | 0/23 (0%) | 5/23 (21.7%) | 10/23 (43.5%) |
| High Dose of Epoetin Alfa: Vadadustat 300 mg | 1/18 (5.6%) | 8/18 (44.4%) | 9/18 (50%) |
| High Dose of Epoetin Alfa: Vadadustat 450 mg | 1/21 (4.8%) | 6/21 (28.6%) | 9/21 (42.9%) |
| High Dose of Epoetin Alfa: Vadadustat 600 mg | 1/21 (4.8%) | 10/21 (47.6%) | 10/21 (47.6%) |
| High Dose of Epoetin Alfa: Epoetin Alfa | 1/13 (7.7%) | 5/13 (38.5%) | 8/13 (61.5%) |
| ESA Hyporesponder: Vadadustat 600 mg | 0/5 (0%) | 4/5 (80%) | 4/5 (80%) |
| ESA Hyporesponder: Epoetin Alfa | 0/5 (0%) | 3/5 (60%) | 2/5 (40%) |
| Event | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| Fluid overloadMetabolism and nutrition disorders | 0/34 | 0/35 | 0/23 | 0/18 | 0/21 | 1/21 | 1/13 | 0/5 | 2/5 |
| AnaemiaBlood and lymphatic system disorders | 0/34 | 0/35 | 0/23 | 0/18 | 0/21 | 0/21 | 0/13 | 1/5 | 0/5 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/34 | 0/35 | 0/23 | 0/18 | 0/21 | 0/21 | 0/13 | 1/5 | 1/5 |
| Non-cardiac chest painGeneral disorders | 0/34 | 0/35 | 0/23 | 0/18 | 0/21 | 0/21 | 0/13 | 0/5 | 1/5 |
| Liver injuryHepatobiliary disorders | 0/34 | 0/35 | 0/23 | 0/18 | 0/21 | 0/21 | 0/13 | 0/5 | 1/5 |
| Staphylococcal bacteraemiaInfections and infestations | 0/34 | 0/35 | 0/23 | 0/18 | 0/21 | 0/21 | 0/13 | 1/5 | 0/5 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/34 | 1/35 | 0/23 | 0/18 | 0/21 | 1/21 | 0/13 | 1/5 | 0/5 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/34 | 0/35 | 0/23 | 0/18 | 0/21 | 0/21 | 0/13 | 0/5 | 1/5 |
| SeizureNervous system disorders | 0/34 | 0/35 | 0/23 | 0/18 | 0/21 | 0/21 | 0/13 | 0/5 | 1/5 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/34 | 0/35 | 0/23 | 0/18 | 0/21 | 0/21 | 1/13 | 0/5 | 1/5 |
| Event | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa |
|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/34 | 3/35 | 4/23 | 4/18 | 2/21 | 4/21 | 1/13 | 1/5 | 0/5 |
| AnaemiaBlood and lymphatic system disorders | 0/34 | 0/35 | 0/23 | 1/18 | 0/21 | 1/21 | 0/13 | 1/5 | 0/5 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/34 | 0/35 | 0/23 | 0/18 | 0/21 | 0/21 | 0/13 | 1/5 | 0/5 |
| Bundle branch block rightCardiac disorders | 0/34 | 0/35 | 0/23 | 0/18 | 0/21 | 0/21 | 0/13 | 0/5 | 1/5 |
| Sinus tachycardiaCardiac disorders | 0/34 | 0/35 | 0/23 | 0/18 | 0/21 | 0/21 | 0/13 | 1/5 | 0/5 |
| TinnitusEar and labyrinth disorders | 0/34 | 0/35 | 0/23 | 0/18 | 0/21 | 0/21 | 0/13 | 1/5 | 0/5 |
| NauseaGastrointestinal disorders | 2/34 | 0/35 | 0/23 | 0/18 | 0/21 | 0/21 | 0/13 | 1/5 | 0/5 |
| PyrexiaGeneral disorders | 0/34 | 0/35 | 0/23 | 0/18 | 0/21 | 0/21 | 0/13 | 0/5 | 1/5 |
| Ulcer haemorrhageGeneral disorders | 0/34 | 0/35 | 0/23 | 0/18 | 0/21 | 0/21 | 0/13 | 1/5 | 0/5 |
| AcarodermatitisInfections and infestations | 0/34 | 0/35 | 0/23 | 0/18 | 0/21 | 0/21 | 0/13 | 1/5 | 0/5 |
| Age, Customized(Participants) | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| <65 years | 20 | 22 | 15 | 11 | 18 | 13 | 7 | 4 | 3 | 113 |
| >=65 years | 15 | 12 | 8 | 7 | 3 | 8 | 6 | 1 | 2 | 62 |
| Sex: Female, Male(Participants) | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 14 | 13 | 4 | 7 | 7 | 9 | 6 | 4 | 3 | 67 |
| Male | 21 | 21 | 19 | 11 | 14 | 12 | 7 | 1 | 2 | 108 |
| Race (NIH/OMB)(Participants) | Low Dose of Epoetin Alfa: Vadadustat 300 mg | Low Dose of Epoetin Alfa: Vadadustat 450 mg | Low Dose of Epoetin Alfa: Epoetin Alfa | High Dose of Epoetin Alfa: Vadadustat 300 mg | High Dose of Epoetin Alfa: Vadadustat 450 mg | High Dose of Epoetin Alfa: Vadadustat 600 mg | High Dose of Epoetin Alfa: Epoetin Alfa | ESA Hyporesponder: Vadadustat 600 mg | ESA Hyporesponder: Epoetin Alfa | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 4 |
| Asian | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 9 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 4 |
| Black or African American | 18 | 19 | 7 | 8 | 13 | 14 | 6 | 2 | 2 | 89 |
| White | 10 | 9 | 13 | 5 | 6 | 5 | 5 | 3 | 0 | 56 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 4 | 1 | 2 | 1 | 0 | 1 | 0 | 0 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2019 to primary completion in Jun 2020, 16 months.
Results were first posted in Sep 2022, 2 years 3 months after primary completion. A results delay was requested in Jun 2021.
Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 16 months is below that.
Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vadadustat